Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers

NCT05527184 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05527184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05527184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 11, 2023
Completion date
February 28, 2027
Enrollment
256 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, fallopian tube cancer, high grade serous adenocarcinoma of ovary, primary peritoneal carcinoma